Gadoxetate disodium-enhanced hepatobiliary phase MRI of hepatocellular carcinoma: Correlation with histological characteristics

American Journal of Roentgenology

Volumn 197, Issue 2, 2011, Pages 399-405

  Choi, Jin Young ^a   Kim, Myeong Jin ^a   Park, Young Nyun ^b   Lee, Jeong Min ^c   Yoo, Sun Kook ^b   Rha, Sun Young ^d   Seok, Jae Yeon ^e  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Seoul National University Hospital   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e Ajou University School of Medicine   (South Korea)

Author keywords

Contrast agent; Hepatocellular carcinoma; MRI

Indexed keywords

CELL ANTIBODY; CYTOKERATIN 19; CYTOKERATIN 7; GADOXETIC ACID;

ADULT; AGED; ANALYTICAL PARAMETERS; ANTIBODY DETECTION; ARTICLE; CANCER GRADING; CELL DENSITY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HEPATOBILIARY RADIOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIGNAL NOISE RATIO;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; KERATIN-19; KERATIN-7; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL;

EID: 79960746888     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.10.5439     Document Type: Article

References (35)

1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340:745-750 (Pubitemid 29114292)
2. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94:153-156 (Pubitemid 32911406)
3. Burrel M, Llovet JM, Ayuso C, et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 2003; 38:1034-1042 (Pubitemid 37221687)
4. Libbrecht L, Bielen D, Verslype C, et al. Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transpl 2002; 8:749-761 (Pubitemid 35012282)
5. Noguchi Y, Murakami T, Kim T, et al. Detection of hepatocellular carcinoma: comparison of dynamic MR imaging with dynamic double arterial phase helical CT. AJR 2003; 180:455-460 (Pubitemid 36135031)
6. Semelka RC, Helmberger TK. Contrast agents for MR imaging of the liver. Radiology 2001; 218:27-38
7. Bartolozzi C, Crocetti L, Lencioni R, Cioni D, Della Pina C, Campani D. Biliary and reticuloendothelial impairment in hepatocarcinogenesis: the diagnostic role of tissue-specific MR contrast media. Eur Radiol 2007; 17:2519-2530
8. Hammerstingl R, Huppertz A, Breuer J, et al. Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol 2008; 18:457-467 (Pubitemid 351248177)
9. Jung G, Breuer J, Poll LW, et al. Imaging characteristics of hepatocellular carcinoma using the hepatobiliary contrast agent Gd-EOB-DTPA. Acta Radiol 2006; 47:15-23 (Pubitemid 43177525)
10. Reimer P, Rummeny EJ, Shamsi K, et al. Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology 1996; 199:177-183 (Pubitemid 26098637)
11. Saito K, Kotake F, Ito N, et al. Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase. Magn Reson Med Sci 2005; 4:1-9
12. Schmitz SA, Haberle JH, Balzer T, Shamsi K, Boese-Landgraf J, Wolf KJ. Detection of focal liver lesions: CT of the hepatobiliary system with gadoxetic acid disodium, or Gd-EOB-DTPA. Radiology 1997; 202:399-405 (Pubitemid 27051734)
13. Vogl TJ, Kummel S, Hammerstingl R, et al. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 1996; 200:59-67 (Pubitemid 26197732)
14. Dahlstrom N, Persson A, Albiin N, Smedby O, Brismar TB. Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects. Acta Radiol 2007; 48:362-368 (Pubitemid 46633865)
15. Dohr O, Hofmeister R, Treher M, Schweinfurth H. Preclinical safety evaluation of Gd-EOB-DTPA (Primovist). Invest Radiol 2007; 42:830-841 (Pubitemid 350126565)
16. Schuhmann-Giampieri G, Mahler M, Roll G, Maibauer R, Schmitz S. Pharmacokinetics of the liver-specific contrast agent Gd-EOB-DTPA in relation to contrast-enhanced liver imaging in humans. J Clin Pharmacol 1997; 37:587-596 (Pubitemid 27443539)
17. Huppertz A, Haraida S, Kraus A, et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT - initial observations. Radiology 2005; 234:468-478 (Pubitemid 40139918)
18. Cruite I, Schroeder M, Merkle EM, Sirlin CB. Gadoxetate disodium-enhanced MRI of the liver. Part 2. Protocol optimization and lesion appearance in the cirrhotic liver. AJR 2010; 195:29-41
19. Fujita M, Yamamoto R, Takahashi M, et al. Paradoxic uptake of Gd-EOB-DTPA by hepatocellular carcinoma in mice: quantitative image analysis. J Magn Reson Imaging 1997; 7:768-770 (Pubitemid 28365630)
20. Ni Y, Marchal G, Yu J, Muhler A, Lukito G, Baert AL. Prolonged positive contrast enhancement with Gd-EOB-DTPA in experimental liver tumors: potential value in tissue characterization. J Magn Reson Imaging 1994; 4:355-363
21. Vogl TJ, Stupavsky A, Pegios W, et al. Hepatocellular carcinoma: evaluation with dynamic and static gadobenate dimeglumine-enhanced MR imaging and histopathologic correlation. Radiology 1997; 205:721-728 (Pubitemid 27516707)
22. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954; 7:462-503
23. Kim JH, Kim MJ, Park YN, et al. Mangafodipir trisodium-enhanced MRI of hepatocellular carcinoma: correlation with histological characteristics. Clin Radiol 2008; 63:1195-1204
24. Fujita M, Yamamoto R, Fritz-Zieroth B, et al. Contrast enhancement with Gd-EOB-DTPA in MR imaging of hepatocellular carcinoma in mice: a comparison with superparamagnetic iron oxide. J Magn Reson Imaging 1996; 6:472-477 (Pubitemid 126707482)
25. Narita M, Hatano E, Arizono S, et al. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol 2009; 44:793-798
26. Frericks BB, Loddenkemper C, Huppertz A, et al. Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA. AJR 2009; 193:1053-1060
27. Grazioli L, Morana G, Caudana R, et al. Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings. Invest Radiol 2000; 35:25-34 (Pubitemid 30033604)
28. Durnez A, Verslype C, Nevens F, et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma: a possible progenitor cell origin. Histopathology 2006; 49:138-151 (Pubitemid 44079697)
29. Uenishi T, Kubo S, Yamamoto T, et al. Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci 2003; 94:851-857 (Pubitemid 37406966)
30. Zhuang PY, Zhang JB, Zhu XD, et al. Two pathologic types of hepatocellular carcinoma with lymph node metastasis with distinct prognosis on the basis of CK19 expression in tumor. Cancer 2008; 112:2740-2748
31. Wu PC, Fang JW, Lau VK, Lai CL, Lo CK, Lau JY. Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers: clinical and biological implications. Am J Pathol 1996; 149:1167-1175 (Pubitemid 26337236)
32. Chu PG, Ishizawa S, Wu E, Weiss LM. Hepatocyte antigen as a marker of hepatocellular carcinoma: an immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein. Am J Surg Pathol 2002; 26:978-988 (Pubitemid 34810558)
33. Kumagai I, Masuda T, Sato S, Ishikawa K. Immunoreactivity to monoclonal antibody, Hep Par 1, in human hepatocellular carcinomas according to histopathological grade and histological pattern. Hepatol Res 2001; 20:312-319 (Pubitemid 32573893)
34. Balci NC, Semelka RC. Contrast agents for MR imaging of the liver. Radiol Clin North Am 2005; 43:887-898 [viii]
35. Cui Y, Konig J, Nies AT, et al. Detection of the human organic anion transporters SLC21A6 (OATP2) and SLC21A8 (OATP8) in liver and hepatocellular carcinoma. Lab Invest 2003; 83:527-538 (Pubitemid 36457707)